{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:05:55Z","timestamp":1787238355296,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome; MPS VI) is an autosomal recessive lysosomal storage disorder in which deficiency of N-acetylgalactosamine 4-sulfatase (arylsulfatase B; ARSB) leads to the storage of glycosaminoglycans (GAGs) in connective tissue. The genotype-phenotype correlation has been addressed in several publications but the picture is not complete. Since 2007, enzyme-replacement therapy (ERT) has been available for patients with MPS VI in the Netherlands. The purpose of our study was to learn more about the genotype-phenotype correlations in MPS VI and the antibody response to ERT with galsulfase (recombinant human arylsulfatase B).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We identified ARSB mutations in 12 patients and used site-directed mutagenesis to study their effect. Antibody levels to galsulfase were measured using ELISA and a semi-quantitative immunoprecipitation method. We assessed the\n                      <jats:italic>in vitro<\/jats:italic>\n                      inhibitory effect of antibodies on galsulfase uptake and their effect on clinical outcome.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Five patients had a rapidly progressive phenotype and seven a slowly progressive phenotype. In total 9 pathogenic mutations were identified including 4 novel mutations (N301K, V332G, A237D, and c.1142\u2009+\u20092\u00a0T\u2009&gt;\u2009C) together composing 8 pathogenic genotypes. Most mutations appeared not to affect the synthesis of ARSB (66 kD precursor), but to hamper its maturation (43 kD ARSB). Disease severity was correlated with urinary GAG excretion. All patients developed antibodies to galsulfase within 26\u00a0weeks of treatment. It was demonstrated that these antibodies can inhibit the uptake of galsulfase\n                      <jats:italic>in vitro<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The clinical phenotypes and the observed defects in the biosynthesis of ARSB show that some of the mutations that we identified are clearly more severe than others. Patients receiving galsulfase as enzyme-replacement therapy can develop antibodies towards the therapeutic protein. Though most titers are modest, they can exceed a level at which they potentially affect the clinical outcome of enzyme-replacement therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/1750-1172-8-51","type":"journal-article","created":{"date-parts":[[2013,4,4]],"date-time":"2013-04-04T06:15:10Z","timestamp":1365056110000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to galsulfase"],"prefix":"10.1186","volume":"8","author":[{"given":"Marion M","family":"Brands","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Hoogeveen-Westerveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian A","family":"Kroos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willemieke","family":"Nobel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George J","family":"Ruijter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lale","family":"\u00d6zkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Plug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Grinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Llu\u00efsa","family":"Vilageliu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dicky J","family":"Halley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ans T van der","family":"Ploeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold J","family":"Reuser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,4,4]]},"reference":[{"key":"554_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1750-1172-5-5","volume":"5","author":"V Valayannopoulos","year":"2010","unstructured":"Valayannopoulos V, Nicely H, Harmatz P, Turbeville S: Mucopolysaccharidosis VI. Orphanet J Rare Dis. 2010, 5: 5-24. 10.1186\/1750-1172-5-5.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"554_CR2","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/jhg.2012.6","volume":"57","author":"S Saito","year":"2012","unstructured":"Saito S, Ohno K, Sekijima M, Suzuki T, Sakuraba H: Database of the clinical phenotypes, genotypes and mutant arylsulfatase B structures in mucopolysaccharidosis type VI. J Hum Genet. 2012, 57 (4): 280-282. 10.1038\/jhg.2012.6.","journal-title":"J Hum Genet"},{"issue":"4","key":"554_CR3","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ymgme.2008.04.001","volume":"94","author":"P Harmatz","year":"2008","unstructured":"Harmatz P, Giugliani R, Schwartz IV, Guffon N, Teles EL, Miranda MC, Wraith JE, Beck M, Arash L, Scarpa M, Ketteridge D, Hopwood JJ, Plecko B, Steiner R, Whitley CB, Kaplan P, Yu ZF, Swiedler SJ, Decker C, MPS VI Study Group: Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol Genet Metab. 2008, 94 (4): 469-475. 10.1016\/j.ymgme.2008.04.001.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"554_CR4","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jpeds.2005.12.014","volume":"148","author":"P Harmatz","year":"2006","unstructured":"Harmatz P, Giugliani R, Schwartz I, Guffon N, Teles EL, Miranda MC, Wraith JE, Beck M, Arash L, Scarpa M, Yu ZF, Wittes J, Berger KI, Newman MS, Lowe AM, Kakkis E, Swiedler SJ, MPS VI Phase 3 Study Group: Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr. 2006, 148 (4): 533-539. 10.1016\/j.jpeds.2005.12.014.","journal-title":"J Pediatr"},{"issue":"1","key":"554_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10545-009-9007-8","volume":"33","author":"P Harmatz","year":"2010","unstructured":"Harmatz P, Yu ZF, Giugliani R, Schwartz IV, Guffon N, Teles EL, Miranda MC, Wraith JE, Beck M, Arash L, Scarpa M, Ketteridge D, Hopwood JJ, Plecko B, Steiner R, Whitley CB, Kaplan P, Swiedler SJ, Hardy K, Berger KI, Decker C: Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J Inherit Metab Dis. 2010, 33 (1): 51-60. 10.1007\/s10545-009-9007-8.","journal-title":"J Inherit Metab Dis"},{"issue":"10","key":"554_CR6","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.molmed.2003.08.004","volume":"9","author":"DA Brooks","year":"2003","unstructured":"Brooks DA, Kakavanos R, Hopwood JJ: Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder. Trends Mol Med. 2003, 9 (10): 450-453. 10.1016\/j.molmed.2003.08.004.","journal-title":"Trends Mol Med"},{"issue":"1","key":"554_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ymgme.2008.10.013","volume":"96","author":"CE Hollak","year":"2009","unstructured":"Hollak CE, Linthorst GE: Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome?. Mol Genet Metab. 2009, 96 (1): 1-3. 10.1016\/j.ymgme.2008.10.013.","journal-title":"Mol Genet Metab"},{"issue":"8","key":"554_CR8","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","volume":"13","author":"SG Banugaria","year":"2011","unstructured":"Banugaria SG, Prater SN, Ng YK, Kobori JA, Finkel RS, Ladda RL, Chen YT, Rosenberg AS, Kishnani PS: The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet Med. 2011, 13 (8): 729-736. 10.1097\/GIM.0b013e3182174703.","journal-title":"Genet Med"},{"issue":"3","key":"554_CR9","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/0009-8981(59)90119-6","volume":"4","author":"H Baum","year":"1959","unstructured":"Baum H, Dodgson KS, Spencer B: The assay of arylsulphatases A and B in human urine. Clin Chim Acta. 1959, 4 (3): 453-455. 10.1016\/0009-8981(59)90119-6.","journal-title":"Clin Chim Acta"},{"issue":"3","key":"554_CR10","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.ymgme.2008.02.012","volume":"94","author":"E Garrido","year":"2008","unstructured":"Garrido E, Cormand B, Hopwood JJ, Chabas A, Grinberg D, Vilageliu L: Maroteaux-Lamy syndrome: functional characterization of pathogenic mutations and polymorphisms in the arylsulfatase B gene. Mol Genet Metab. 2008, 94 (3): 305-312. 10.1016\/j.ymgme.2008.02.012.","journal-title":"Mol Genet Metab"},{"issue":"10","key":"554_CR11","doi-asserted-by":"crossref","first-page":"4937","DOI":"10.1016\/S0021-9258(19)85585-0","volume":"255","author":"A Hasilik","year":"1980","unstructured":"Hasilik A, Neufeld EF: Biosynthesis of lysosomal enzymes in fibroblasts. Synthesis as precursors of higher molecular weight. J Biol Chem. 1980, 255 (10): 4937-4945.","journal-title":"J Biol Chem"},{"issue":"6","key":"554_CR12","first-page":"1127","volume":"58","author":"T Litjens","year":"1996","unstructured":"Litjens T, Brooks DA, Peters C, Gibson GJ, Hopwood JJ: Identification, expression, and biochemical characterization of N-acetylgalactosamine-4-sulfatase mutations and relationship with clinical phenotype in MPS-VI patients. Am J Hum Genet. 1996, 58 (6): 1127-1134.","journal-title":"Am J Hum Genet"},{"issue":"4","key":"554_CR13","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/humu.1190","volume":"18","author":"T Litjens","year":"2001","unstructured":"Litjens T, Hopwood JJ: Mucopolysaccharidosis type VI: Structural and clinical implications of mutations in N-acetylgalactosamine-4-sulfatase. Hum Mutat. 2001, 18 (4): 282-295. 10.1002\/humu.1190.","journal-title":"Hum Mutat"},{"issue":"2","key":"554_CR14","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ymgme.2011.11.003","volume":"105","author":"A Jurecka","year":"2012","unstructured":"Jurecka A, Piotrowska E, Cimbalistiene L, Gusina N, Sobczynska A, Czartoryska B, Czerska K, Ounap K, Wegrzyn G, Tylki-Szymanska A: Molecular analysis of mucopolysaccharidosis type VI in Poland, Belarus, Lithuania and Estonia. Mol Genet Metab. 2012, 105 (2): 237-243. 10.1016\/j.ymgme.2011.11.003.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"554_CR15","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.ymgme.2011.09.017","volume":"104","author":"FM Costa-Motta","year":"2011","unstructured":"Costa-Motta FM, Acosta AX, Abe-Sandes K, Bender F, Schwartz IV, Giugliani R, Leistner-Segal S: Genetic studies in a cluster of mucopolysaccharidosis type VI patients in Northeast Brazil. Mol Genet Metab. 2011, 104 (4): 603-607. 10.1016\/j.ymgme.2011.09.017.","journal-title":"Mol Genet Metab"},{"issue":"12","key":"554_CR16","first-page":"820","volume":"100","author":"CF Yang","year":"2001","unstructured":"Yang CF, Wu JY, Lin SP, Tsai FJ: Mucopolysaccharidosis type VI: Report of two Taiwanese patients and identification of one novel mutation. J Formos Med Assoc. 2001, 100 (12): 820-823.","journal-title":"J Formos Med Assoc"},{"issue":"3","key":"554_CR17","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/BF00212019","volume":"93","author":"E Voskoboeva","year":"1994","unstructured":"Voskoboeva E, Isbrandt D, von Figura K, Krasnopolskaya X, Peters C: Four novel mutant alleles of the arylsulfatase B gene in two patients with intermediate form of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Hum Genet. 1994, 93 (3): 259-264. 10.1007\/BF00212019.","journal-title":"Hum Genet"},{"issue":"3","key":"554_CR18","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ymgme.2011.03.024","volume":"103","author":"I Gottwald","year":"2011","unstructured":"Gottwald I, Hughes J, Stewart F, Tylee K, Church H, Jones SA: Attenuated mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome) due to homozygosity for the p.Y210C mutation in the ARSB gene. Mol Genet Metab. 2011, 103 (3): 300-302. 10.1016\/j.ymgme.2011.03.024.","journal-title":"Mol Genet Metab"},{"issue":"9","key":"554_CR19","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1002\/humu.20534","volume":"28","author":"L Karageorgos","year":"2007","unstructured":"Karageorgos L, Brooks DA, Pollard A, Melville EL, Hein LK, Clements PR, Ketteridge D, Swiedler SJ, Beck M, Giugliani R, Harmatz P, Wraith JE, Guffon N, Leao Teles E, Sa Miranda MC, Hopwood JJ: Mutational analysis of 105 mucopolysaccharidosis type VI patients. Hum Mutat. 2007, 28 (9): 897-903. 10.1002\/humu.20534.","journal-title":"Hum Mutat"},{"issue":"3","key":"554_CR20","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1042\/bj2340507","volume":"234","author":"JJ Hopwood","year":"1986","unstructured":"Hopwood JJ, Elliott H, Muller VJ, Saccone GT: Diagnosis of Maroteaux-Lamy syndrome by the use of radiolabelled oligosaccharides as substrates for the determination of arylsulphatase B activity. Biochem J. 1986, 234 (3): 507-514.","journal-title":"Biochem J"},{"issue":"4","key":"554_CR21","first-page":"710","volume":"48","author":"DA Brooks","year":"1991","unstructured":"Brooks DA, McCourt PA, Gibson GJ, Ashton LJ, Shutter M, Hopwood JJ: Analysis of N-acetylgalactosamine-4-sulfatase protein and kinetics in mucopolysaccharidosis type VI patients. Am J Hum Genet. 1991, 48 (4): 710-719.","journal-title":"Am J Hum Genet"},{"issue":"2","key":"554_CR22","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/ajmg.a.30579","volume":"134A","author":"SJ Swiedler","year":"2005","unstructured":"Swiedler SJ, Beck M, Bajbouj M, Giugliani R, Schwartz I, Harmatz P, Wraith JE, Roberts J, Ketteridge D, Hopwood JJ, Guffon N, Sa Miranda MC, Teles EL, Berger KI, Piscia-Nichols C: Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Am J Med Genet A. 2005, 134A (2): 144-150. 10.1002\/ajmg.a.30579.","journal-title":"Am J Med Genet A"},{"issue":"4","key":"554_CR23","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.ymgme.2011.08.024","volume":"104","author":"A Jurecka","year":"2011","unstructured":"Jurecka A, Golda A, Opoka-Winiarska V, Piotrowska E, Tylki-Szymanska A: Mucopolysaccharidosis Type VI (Maroteaux-Lamy syndrome) with a predominantly cardiac phenotype. Mol Genet Metab. 2011, 104 (4): 695-9. 10.1016\/j.ymgme.2011.08.024.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"554_CR24","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1093\/nar\/10.2.459","volume":"10","author":"SM Mount","year":"1982","unstructured":"Mount SM: A catalogue of splice junction sequences. Nucleic Acids Res. 1982, 10 (2): 459-472. 10.1093\/nar\/10.2.459.","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"554_CR25","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s10545-012-9474-1","volume":"35","author":"A Thumler","year":"2012","unstructured":"Thumler A, Miebach E, Lampe C, Pitz S, Kamin W, Kampmann C, Link B, Mengel E: Clinical characteristics of adults with slowly progressing mucopolysaccharidosis VI: a case series. J Inherit Metab Dis. 2012, 35 (6): 1071-9. 10.1007\/s10545-012-9474-1.","journal-title":"J Inherit Metab Dis"},{"issue":"13","key":"554_CR26","doi-asserted-by":"crossref","first-page":"9638","DOI":"10.1016\/S0021-9258(17)36929-6","volume":"269","author":"G Arlt","year":"1994","unstructured":"Arlt G, Brooks DA, Isbrandt D, Hopwood JJ, Bielicki J, Bradford TM, Bindloss-Petherbridge CA, von Figura K, Peters C: Juvenile form of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). A C-terminal extension causes instability but increases catalytic efficiency of arylsulfatase B. J Biol Chem. 1994, 269 (13): 9638-9643.","journal-title":"J Biol Chem"},{"issue":"3","key":"554_CR27","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrm1052","volume":"4","author":"L Ellgaard","year":"2003","unstructured":"Ellgaard L, Helenius A: Quality control in the endoplasmic reticulum. Nat Rev Mol Cell Biol. 2003, 4 (3): 181-191.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"15","key":"554_CR28","doi-asserted-by":"publisher","first-page":"4962","DOI":"10.1021\/bi0121149","volume":"41","author":"TM Bradford","year":"2002","unstructured":"Bradford TM, Litjens T, Parkinson EJ, Hopwood JJ, Brooks DA: Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome): a Y210C mutation causes either altered protein handling or altered protein function of N-acetylgalactosamine 4-sulfatase at multiple points in the vacuolar network. Biochemistry. 2002, 41 (15): 4962-4971. 10.1021\/bi0121149.","journal-title":"Biochemistry"},{"key":"554_CR29","volume-title":"Mol Genet Metab","author":"MM Brands","year":"2013","unstructured":"Brands MM, Oussoren E, Ruijter GJ, Vollebregt AA, van den Hout HM, Joosten KF, Hop WC, Plug I, van der Ploeg AT: Up to five years experience with 11 mucopolysaccharidosis type VI patients. Mol Genet Metab. 2013, 10.1016\/j.ymgme.2013.02.013."},{"issue":"2","key":"554_CR30","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s10545-011-9400-y","volume":"35","author":"PB Deegan","year":"2012","unstructured":"Deegan PB: Fabry disease, enzyme replacement therapy and the significance of antibody responses. J Inherit Metab Dis. 2012, 35 (2): 227-243. 10.1007\/s10545-011-9400-y.","journal-title":"J Inherit Metab Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1750-1172-8-51.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T19:07:31Z","timestamp":1630523251000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/1750-1172-8-51"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,4]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["554"],"URL":"https:\/\/doi.org\/10.1186\/1750-1172-8-51","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,4]]},"assertion":[{"value":"3 January 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"51"}}